JMP says Pfizer data ‘impressive,’ but leave room for Alnylam’s Onpattro

 JMP Securities analyst Konstantinos Aprilakis said Pfizer’s (PFE) tafamidis demonstrated an “impressive” reduction in both all-cause mortality and cardiovascular-related hospitalization in patients with TTR amyloid cardiomyopathy, but he still sees “significant opportunity” for Alnylam’s (ALNY) Onpattro to capture market share given the lack of statistically significant benefit for tafamidis in hereditary vs. wild-type patients and the lack of apparent dose response effect between 80mg and 20mg doses of tafamidis. He maintains an Outperform rating and $198 price target on Alnylam, saying the Pfizer readout removed a significant overhang on the shares.

https://bit.ly/2oiKLF8